SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Chinook Therapeutics, Inc. (KDNY) .
Criteria proven by this page:
- VALUE (10/100, Fail) — analyst consensus target implies downside from the current price ($30.00, 25.7%).
- Analyst consensus target $30.00 (-25.7% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 30/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — KDNY
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio424.27
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.87
Book Value / Share$0.00
Revenue / Share$0.10
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$30.00 (-25.7%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$0.00 |
$72.98M |
$-39.21M |
-53.7% |
| 2016 |
$0.00 |
$50.68M |
$-91.15M |
-179.8% |
| 2017 |
$0.00 |
$17.24M |
$-91.86M |
-532.9% |
| 2018 |
$0.00 |
$15.09M |
$-95.36M |
-632% |
| 2019 |
$-1.11 |
$17.26M |
$-46.85M |
-271.5% |
| 2020 |
$-6.20 |
$827K |
$-81.62M |
-9869.6% |
| 2021 |
$-2.22 |
$51.63M |
$-101.3M |
-196.2% |
| 2022 |
$-2.87 |
$6.13M |
$-184.62M |
-3012.6% |
